Tumor-agnostic therapy is the idea that a molecular or genetic alteration in a tumor can be targeted by a therapy, regardless of the tumors location in the body (link). This requires that the tumor be interrogated for specific mutations and alterations that allow it to be specifically targeted. This differs vastly from the traditional developmental thought process for oncology drugs where candidates were developed based on a locations and type of tumor they targeted (i.e. lung, liver, breast, etc.). To my knowledge, there are only two FDA-approved tumor agnostic labeled indications: Merck's (MRK) pembrolizumab and LOXO . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.